Tokai Pharmaceuticals Appoints Gerald Quirk as General Counsel and Executive Vice President, Business Operations
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) , a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Gerald Quirk as General Counsel and Executive Vice President, Business Operations. Mr. Quirk brings to Tokai more than twenty years of experience advancing the legal and business interests of public biopharmaceutical companies, including the development and commercialization of oncology products.
“We are delighted to have Gerald round out Tokai’s management team. He has been a trusted advisor to the company over the past several years, successfully integrating his legal acumen with his broad oncology company experience,” stated Jodie Morrison, President and Chief Executive Officer of Tokai Pharmaceuticals. “With responsibility for legal and intellectual property matters, as well as business operations functions, we expect Gerald will contribute significantly to the advancement of galeterone through Phase 3 development and commercial launch, as well as the expansion of our Androgen Receptor Degrading Agents platform.”
Prior to joining Tokai, Mr. Quirk was a partner and co-chair of the life sciences practice at Choate, Hall & Stewart LLP, a Boston law firm. In this role, Mr. Quirk represented leading biopharmaceutical companies in corporate and securities law matters, financing and M&A transactions, and licensing and product development transactions. Prior to joining Choate, he was Vice President, Corporate Affairs and General Counsel at Infinity Pharmaceuticals with responsibility for the company’s legal, intellectual property, finance and corporate communications activities, and held progressively responsible legal and business development positions at Genzyme Corporation. Mr. Quirk holds a B.A. in political science from Swarthmore College, an Ed.M. in educational administration from Harvard University, and a J.D. from Northeastern University.
“I am excited to be joining Tokai and have confidence in the promise of galeterone for men with castration-resistant prostate cancer,” said Mr. Quirk. “With global commercial rights to galeterone, an efficient Phase 3 clinical trial poised to begin this quarter, and a strong balance sheet, I believe Tokai is well-positioned to make a meaningful difference in the lives of patients.”
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate being developed for the treatment of patients with castration-resistant prostate cancer. The Company’s ARDA drug discovery program is focused on the identification and evaluation of compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation and are targeted to patients with androgen receptor signaling diseases, including prostate cancer. For more information on the Company and galeterone, please visit www.tokaipharma.com.
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, intellectual property, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the Company’s cash resources will be sufficient to fund the Company’s continuing operations for the period anticipated; whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials; whether galeterone will advance through the clinical trial process on the anticipated timeline, including whether ARMOR3-SV will be initiated when anticipated; whether a companion diagnostic can be developed successfully and on a timely basis; whether the results of ARMOR3-SV will warrant submission for regulatory approval of galeterone and whether such submission will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if galeterone obtains such approval, it will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of the Company’s quarterly report on Form 10-Q for the three months ended March 31, 2015. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any subsequent date. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Sorry. No data so far.